Search 

Helsinn is a privately owned pharmaceutical group with an extensive portfolio of marketed cancer care products and a robust drug development pipeline. Since 1976, Helsinn has been improving the everyday lives of patients, guided by core family values of respect, integrity and quality. The Group works across pharmaceuticals, biotechnology, medical devices and nutritional supplements and has expertise in research, development, manufacture and the commercialization of therapeutic and supportive care products for cancer, pain and inflammation and gastroenterology. In 2016, Helsinn created the Helsinn Investment Fund to support early-stage investment opportunities in areas of unmet patient need. Since 2012, Helsinn has been coordinating clinical and regulatory activities in China from Beijing and in 2017 established an office in Shanghai to pursue commercial activities. The company is headquartered in Lugano, Switzerland, with operating subsidiaries in Switzerland, Ireland, and the U.S., as well as a product presence in approximately 190 countries globally.

Luye Pharma Group is an international pharmaceutical company dedicated to the R&D, manufacturing and sale of innovative medications. The company has established R&D centers in China, the U.S. and the EU, with a robust pipeline of 30 drug candidates in China and more than 10 drug candidates overseas. The company currently has a number of new drugs and new formulations in the central nervous system and oncology therapeutic areas under study in the U.S. and the EU. Luye Pharma is a global cutting edge company in terms of research into new drug delivery technologies, such as microspheres, liposomes and transdermal drug delivery systems. The company is forward looking, with strategic development of innovative new compounds and antibodies, gene & cell therapies and smart formulations.

Luye Pharma has set up 7 manufacturing sites with over 30 production lines in total, establishing GMP quality management and international standard control systems. The company offers more than 30 products covering the 4 largest and fastest growing therapeutic areas — oncology, cardiovascular, metabolism and central nervous system, with business conducted in over 80 countries and regions around the world, including the largest pharmaceutical markets - China, the U.S., the EU and Japan, as well as fast growing emerging markets.

Max Zeller Söhne AG specialises in the development, production and marketing of phyto-pharmaceuticals with clinically proven efficacy, safety and tolerability. 

Zeller is a leader in the Swiss market for phyto-pharmaceuticals and one of the few companies that controls the entire value chain from seed to finished product. At the Zeller sites in Romanshorn and Uttwil (VitaPlant), there are 135 employees in diverse disciplines such as biology, agriculture, process engineering, pharmacy and medicine. Patients benefit from Zeller’s phyto-pharmaceuticals both in Switzerland and worldwide.

MergerMotives GmbH - The M&A Consulting Boutique

"Customized support for Mergers & Acquisitions, In- and Outlicensing, Business Development and other related areas".

We are a small and specialized M&A consulting boutique with a young and innovative mindset that is advising and supporting its clients in Mergers & Acquisitions, In- and Outlicensing, Business Succession, Business Development and other related areas. Our clients are companies from various industries all around the world that either do not have their own Business Development team or that need some additional temporary resources for their M&A team.